News

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.
French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...